123 related articles for article (PubMed ID: 37941520)
1. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
[TBL] [Abstract][Full Text] [Related]
2. Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts.
Uruski P; Mikuła-Pietrasik J; Pakuła M; Budkiewicz S; Drzewiecki M; Gaiday AN; Wierzowiecka M; Naumowicz E; Moszyński R; Tykarski A; Książek K
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921783
[TBL] [Abstract][Full Text] [Related]
3. Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro.
Uruski P; Sepetowska A; Konieczna C; Pakuła M; Wyrwa M; Tussupkaliyev A; Tykarski A; Mikuła-Pietrasik J; Książek K
Cell Mol Biol Lett; 2021 Oct; 26(1):44. PubMed ID: 34674640
[TBL] [Abstract][Full Text] [Related]
4. Senescence-related deterioration of intercellular junctions in the peritoneal mesothelium promotes the transmesothelial invasion of ovarian cancer cells.
Pakuła M; Witucka A; Uruski P; Radziemski A; Moszyński R; Szpurek D; Maksin K; Woźniak A; Sajdak S; Tykarski A; Mikuła-Pietrasik J; Książek K
Sci Rep; 2019 May; 9(1):7587. PubMed ID: 31110245
[TBL] [Abstract][Full Text] [Related]
5. Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis.
Rutecki S; Szulc P; Pakuła M; Uruski P; Radziemski A; Naumowicz E; Moszyński R; Tykarski A; Mikuła-Pietrasik J; Książek K
J Ovarian Res; 2022 Jul; 15(1):87. PubMed ID: 35883110
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress contributes to hepatocyte growth factor-dependent pro-senescence activity of ovarian cancer cells.
Mikuła-Pietrasik J; Uruski P; Pakuła M; Maksin K; Szubert S; Woźniak A; Naumowicz E; Szpurek D; Tykarski A; Książek K
Free Radic Biol Med; 2017 Sep; 110():270-279. PubMed ID: 28652056
[TBL] [Abstract][Full Text] [Related]
8. L-Carnosine Prevents the Pro-cancerogenic Activity of Senescent Peritoneal Mesothelium Towards Ovarian Cancer Cells.
Mikuła-Pietrasik J; Książek K
Anticancer Res; 2016 Feb; 36(2):665-71. PubMed ID: 26851022
[TBL] [Abstract][Full Text] [Related]
9. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
10. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
[TBL] [Abstract][Full Text] [Related]
11. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.
Yasui H; Kajiyama H; Tamauchi S; Suzuki S; Peng Y; Yoshikawa N; Sugiyama M; Nakamura K; Kikkawa F
Clin Exp Metastasis; 2020 Feb; 37(1):145-158. PubMed ID: 31541326
[TBL] [Abstract][Full Text] [Related]
12. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
13. Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer.
Wang L; Xiong B; Lu W; Cheng Y; Zhu J; Ai G; Zhang X; Liu X; Cheng Z
Biomed Pharmacother; 2024 May; 174():116474. PubMed ID: 38518604
[TBL] [Abstract][Full Text] [Related]
14. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
15. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
17. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
18. Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo.
Mikuła-Pietrasik J; Sosińska P; Naumowicz E; Maksin K; Piotrowska H; Woźniak A; Szpurek D; Książek K
Clin Exp Metastasis; 2016 Jan; 33(1):15-27. PubMed ID: 26433963
[TBL] [Abstract][Full Text] [Related]
19. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
[TBL] [Abstract][Full Text] [Related]
20. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Sereni MI; Baldelli E; Gambara G; Ravaggi A; Hodge KA; Alberts DS; Guillen-Rodriguez JM; Dong T; Memo M; Odicino F; Angioli R; Liotta LA; Pecorelli SL; Petricoin EF; Pierobon M
Br J Cancer; 2017 Aug; 117(4):494-502. PubMed ID: 28664915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
